{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:41:35Z","timestamp":1760146895677,"version":"3.37.3"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[1995,1,1]],"date-time":"1995-01-01T00:00:00Z","timestamp":788918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,28]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Twenty-one patients with primary immunoglobulin deficiency were enrolled in a crossover study to test the efficacy and safety of Alphaglobin in comparison with the licensed preparations Sandoglobulin and Gamimune. There was no statistical difference in these parameters between Alphaglobin and Sandoglobulin\/Gamimune. The level of total serum IgG and specific IgG to pneumococcal polysaccharides was similar in individual patients when they were receiving Alphaglobin or one of the other products. Transient increases in serum alanine transferase occurred in five patients on Sandoglobulin\/Gamimune and two patients on Alphaglobin. Some patients showed a rise in total serum IgM afterwards, indicating a response to infection. However, serum hepatitis C virus (HCV) RNA was not found during the alanine transferase (ALT) rises, and IgM antibody to hepatitis A virus (HAV) was negative afterwards. We conclude that Alphaglobin is a safe, well tolerated and clinically efficacious treatment for patients with primary antibody deficiency.<\/jats:p>","DOI":"10.1111\/j.1365-2249.1995.tb03465.x","type":"journal-article","created":{"date-parts":[[2010,7,26]],"date-time":"2010-07-26T21:31:23Z","timestamp":1280179883000},"page":"10-15","source":"Crossref","is-referenced-by-count":6,"title":["A prospective controlled crossover trial of a new heat-treated intravenous immunoglobulin"],"prefix":"10.1093","volume":"99","author":[{"given":"S R","family":"Zuhrie","sequence":"first","affiliation":[{"name":"Immunodeficiency Research Group, Clinical Research Centre, Harrow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A D B","family":"Webster","sequence":"additional","affiliation":[{"name":"Immunodeficiency Research Group, Clinical Research Centre, Harrow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Davies","sequence":"additional","affiliation":[{"name":"Alpha Therapeutic VK Ltd., Thetford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A C M","family":"Fay","sequence":"additional","affiliation":[{"name":"Immunology Department, Newcastle General Hospital, Newcastle upon Tyne, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T B","family":"Wallington","sequence":"additional","affiliation":[{"name":"South Western Regional Transfusion Centre, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"2022011517425502200_b1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-94-009-1275-5_3","article-title":"Immunoglobulin replacement therapy","volume-title":"Immunodeficiency and Disease Immunology & Medicine Series","author":"Cunningham-Rundles","year":"1988"},{"key":"2022011517425502200_b2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3101(24)00173-7","article-title":"Human gammaglobulin as therapeutic agents","volume":"35","author":"Stiehm","year":"1988","journal-title":"Adv Pediatr"},{"key":"2022011517425502200_b3","first-page":"1074","article-title":"Epidemic hepatitis B caused by commercial human immunoglobulin","volume":"1","author":"John","year":"1976","journal-title":"Lancet"},{"key":"2022011517425502200_b4","first-page":"668","article-title":"Immunoglobulins and hepatitis","volume-title":"Clinical use of intravenous immunoglobulins","author":"Trepo","year":"1986"},{"key":"2022011517425502200_b5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0140-6736(84)91506-X","article-title":"Non-A non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin","volume":"2","author":"Lever","year":"1984","journal-title":"Lancet"},{"key":"2022011517425502200_b6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0140-6736(85)91430-8","article-title":"Non-A, non-B hepatitis and intravenous immunoglobulin","volume":"1","author":"Ochs","year":"1985","journal-title":"Lancet"},{"key":"2022011517425502200_b7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1423-0410.1989.tb04977.x","article-title":"Transmission of non-A. non-B hepatitis by pH4-treated intravenous gammaglobulin","volume":"57","author":"Williams","year":"1989","journal-title":"Vox Sang"},{"key":"2022011517425502200_b8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0002-9343(88)90016-2","article-title":"Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogamma-globulinaemia or IgG subclass deficiency","volume":"84","author":"Bjorkander","year":"1988","journal-title":"Am J Med"},{"key":"2022011517425502200_b9","first-page":"455","article-title":"Hepatitis C virus transmission by intravenous immunoglobulin","volume":"21","author":"Yap","year":"1994","journal-title":"J Hematol"},{"key":"2022011517425502200_b10","first-page":"1","article-title":"Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia","volume":"76","author":"Garbet","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"2022011517425502200_b11","first-page":"361","article-title":"Blood protein derivative viral safety: observations and analysis","volume":"63","author":"Horowitz","year":"1990","journal-title":"Yale J Biol Med"},{"key":"2022011517425502200_b12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jmv.1890360311","article-title":"Virus safety of human immunoglobulin: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedures","volume":"36","author":"Nowak","year":"1992","journal-title":"J Med Virol"},{"key":"2022011517425502200_b13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1423-0410.1989.tb02019.x","article-title":"Inactivation and elimination of viruses during the fractionation of an intravenous immunoglobulin preparation: liquid heat treatment and polyethylene glycol fractionation","volume":"56","author":"Uemura","year":"1989","journal-title":"Vox Sang"},{"key":"2022011517425502200_b14","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/0140-6736(91)92775-W","article-title":"Improvement of HCV genome detection with \u2018short\u2019 PCR products","volume":"338","author":"Garson","year":"1991","journal-title":"Lancet"},{"key":"2022011517425502200_b15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","article-title":"An analysis of variance test for normality (complete samples)","volume":"52","author":"Shapiro","year":"1965","journal-title":"Biometrika"},{"key":"2022011517425502200_b16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00441919","article-title":"Clinical trials of a sulfonated immunoglobulin preparation for intravenous administration. II Adverse reactions","volume":"136","author":"Matsumoto","year":"1981","journal-title":"Eur J Pediat."},{"key":"2022011517425502200_b17","first-page":"457","article-title":"Intravenous immunoglobulin: current concepts and application","volume-title":"New concepts in immunodeficiency disease","author":"Chapel","year":"1993"},{"key":"2022011517425502200_b18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1423-0410.1987.tb04919.x","article-title":"Elimination of viruses (human immunodeficiency, hepatitis B, vesicular stomatitis and sindbis viruses) from an intravenous immunoglobulin preparation","volume":"53","author":"Hamamoto","year":"1987","journal-title":"Vox Sang"},{"key":"2022011517425502200_b19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00239746","article-title":"The development of virus Tree blood derivatives- a review","volume":"3","author":"Prince","year":"1987","journal-title":"Eur J Epidemiol"},{"key":"2022011517425502200_b20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/0140-6736(92)91955-8","article-title":"Outbreak of hepatitis A among Italian patients with haemophilia","volume":"339","author":"Manucci","year":"1992","journal-title":"Lancet"},{"key":"2022011517425502200_b21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0140-6736(90)91124-S","article-title":"Hepatitis C antibody and chronic liver disease in haemophilia","volume":"1","author":"Makris","year":"1990","journal-title":"Lancet"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.1995.tb03465.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/99\/1\/10\/42202081\/j.1365-2249.1995.tb03465.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/99\/1\/10\/42202081\/j.1365-2249.1995.tb03465.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T10:42:09Z","timestamp":1740307329000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/99\/1\/10\/6484244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,6,28]]},"published-print":{"date-parts":[[2008,6,28]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.1995.tb03465.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"type":"electronic","value":"1365-2249"},{"type":"print","value":"0009-9104"}],"subject":[],"published-other":{"date-parts":[[1995,1]]},"published":{"date-parts":[[1995,1]]}}}